Biocartis Group NV
BCART.BR
| Exchange: | BR |
| Currency | Euro |
| ISIN: | BE0974281132 |
| LEI: | 549300J4HOJL5KG8HY54 |
| Primary Ticker: | BCART.BR |
| Fiscal Year End: | December |
| International Domestic: | International |
| Sector: | Healthcare |
| Industry: | Diagnostics & Research |
| Gic Sector: | Health Care |
| Gic Group: | Health Care Equipment & Services |
| Gic Industry: | Health Care Equipment & Supplies |
| Gic Sub Industry: | Health Care Equipment |
| Description: | Biocartis Group NV, a molecular diagnostics company, provides diagnostic solutions enhancing clinical practice for the benefit of patients, clinicians, payers, and healthcare industry with a focus on oncology. Its proprietary molecular diagnostics Idylla platform is a real-time polymerase chain reaction system that offers molecular information that allows treatment selection and treatment progress monitoring. The company offers Idylla BRAF, KRAS, MSI, EGFR, and NRAS-BRAF mutation tests; and Idylla SARS-Co V-2/Flu/RSV panels and SARS-Co V-2 tests, as well as Septi Cyte RAPID, a rapid host-response test. It also provides research products, including MSI, KRAS, BRAF, ct EGFR, NRAS-BRAF-EGFR S492R, ct KRAS, EGFR, Gene Fusion, ct BRAF, and ct NRAS-BRAF-EGFR S492R mutation assays. The company has a collaboration agreement with Amgen to evaluate Idylla RAS testing as a tool for rapid decentralized testing and/or to accelerate access to RAS biomarker information using Idylla platform and RAS tests; and Bristol-Myers Squibb Company for the registration of diagnostic and use of the Idylla MSI test in connection with immuno-oncology therapies. It also has a license, development, and commercialization agreement with Genepro Dx for the development of Thyroid Print novel genomic test on the Idylla platform; and collaboration with APIS Assay Technologies Ltd. to develop and commercialize breast cancer subtyping test on the Idylla platform. The company was founded in 2007 and is headquartered in Mechelen, Belgium. |
| Address: | Generaal de Wittelaan 11 B, Mechelen, Belgium, 2800 |
| Website: | https://www.biocartisgroupnv.be |
| Full Time Employees: | 526 |
| Updated On: | 2024-07-15 |
Highlights
| Market Capitalization: | 27235612 |
| Market Capitalization Mln: | 27.23 |
| EBITDA: | -37015000 |
| Book Value: | -0.57 |
| Earnings Share: | -0.92 |
| Most Recent Quarter: | 2023-06-30 |
| Profit Margin: | -1.11 |
| Operating Margin TTM: | -0.70 |
| Return On Assets TTM: | -0.24 |
| Return On Equity TTM: | -48.83 |
| Revenue TTM: | 60822000 |
| Revenue Per Share TTM: | 0.77 |
| Quarterly Revenue Growth YOY: | 0.10 |
| Gross Profit TTM: | -10216000 |
| Diluted Eps TTM: | -0.92 |
Valuation
| Price Sales TTM: | 0.44 |
| Price Book MRQ: | 6.46 |
| Enterprise Value: | 154106080 |
| Enterprise Value Revenue: | 2.54 |
| Enterprise Value Ebitda: | -3.71 |
Shares
| Shares Outstanding: | 93915904 |
| Shares Float: | 86566184 |
| Percent Insiders: | 6.58 |
| Percent Institutions: | 26.58 |
Technicals
| Beta: | 1.32 |
| 52 Week High: | 0.29 |
| 52 Week Low: | 0.28 |
| 50 Day MA: | 0.29 |
| 200 Day MA: | 0.29 |
Splits & Dividends
| Last Split Factor: | 783:683 |
| Last Split Date: | 2022-11-17 |
Earnings
| Report Date: | 2023-02-23 |
| Date: | 2022-12-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.79 |
| Report Date: | 2022-10-20 |
| Date: | 2022-09-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Report Date: | 2022-09-01 |
| Date: | 2022-06-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.5 |
| Report Date: | 2022-04-19 |
| Date: | 2022-03-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Report Date: | 2022-02-24 |
| Date: | 2021-12-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -1.26 |
| Eps Difference: | -1.26 |
| Report Date: | 2021-11-10 |
| Date: | 2021-09-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Report Date: | 2021-08-26 |
| Date: | 2021-06-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.65 |
| Eps Difference: | -0.65 |
| Report Date: | 2021-02-25 |
| Date: | 2020-12-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.56 |
| Eps Difference: | -0.56 |
| Report Date: | 2020-09-03 |
| Date: | 2020-06-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.56 |
| Eps Difference: | -0.56 |
| Report Date: | 2020-03-05 |
| Date: | 2019-12-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.56 |
| Eps Difference: | -0.56 |
| Report Date: | 2019-09-05 |
| Date: | 2019-06-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.53 |
| Eps Difference: | -0.53 |
| Report Date: | 2019-03-01 |
| Date: | 2018-12-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.52 |
| Eps Difference: | -0.52 |
| Report Date: | 2018-09-06 |
| Date: | 2018-06-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.42 |
| Eps Difference: | -0.42 |
| Report Date: | 2018-04-26 |
| Date: | 2018-03-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.39 |
| Eps Difference: | -0.39 |
| Report Date: | 2017-09-07 |
| Date: | 2017-06-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.54 |
| Eps Difference: | -0.54 |
| Report Date: | 2017-03-02 |
| Date: | 2016-12-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.63 |
| Eps Difference: | -0.63 |
| Report Date: | 2016-09-06 |
| Date: | 2016-06-30 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.59 |
| Eps Difference: | -0.59 |
| Report Date: | 2016-03-17 |
| Date: | 2015-12-31 |
| Before After Market: | Before Market |
| Currency: | EUR |
| Eps Actual: | -0.62 |
| Eps Difference: | -0.62 |
| Date: | 2024-12-31 |
| Period: | +1y |
| Growth: | 0.59 |
| Earnings Estimate Year Ago Eps: | -0.32 |
| Earnings Estimate Growth: | 0.59 |
| Revenue Estimate Avg: | 76000000.00 |
| Revenue Estimate Low: | 76000000.00 |
| Revenue Estimate High: | 76000000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Revenue Estimate Growth: | 0.31 |
| Eps Trend7days Ago: | -0.13 |
| Eps Trend30days Ago: | -0.13 |
| Eps Trend60days Ago: | -0.13 |
| Eps Trend90days Ago: | -0.13 |
| Date: | 2023-12-31 |
| Growth: | 0.70 |
| Earnings Estimate Year Ago Eps: | -1.08 |
| Earnings Estimate Growth: | 0.70 |
| Revenue Estimate Avg: | 58000000.00 |
| Revenue Estimate Low: | 58000000.00 |
| Revenue Estimate High: | 58000000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Eps Trend7days Ago: | -0.32 |
| Eps Trend30days Ago: | -0.32 |
| Eps Trend60days Ago: | -0.32 |
| Eps Trend90days Ago: | -0.32 |
| Date: | 2023-09-30 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Date: | 2023-06-30 |
| Revenue Estimate Avg: | 1000000.00 |
| Revenue Estimate Low: | 1000000.00 |
| Revenue Estimate High: | 1000000.00 |
| Revenue Estimate Number Of Analysts: | 1.00 |
| Date: | 2023-03-31 |
| Date: | 2022-12-31 |
| Growth: | 0.54 |
| Earnings Estimate Avg: | -0.50 |
| Earnings Estimate Low: | -0.50 |
| Earnings Estimate High: | -0.50 |
| Earnings Estimate Year Ago Eps: | -1.10 |
| Earnings Estimate Number Of Analysts: | 1.00 |
| Earnings Estimate Growth: | 0.54 |
| Revenue Estimate Avg: | 55900000.00 |
| Revenue Estimate Low: | 54800000.00 |
| Revenue Estimate High: | 57000000.00 |
| Revenue Estimate Number Of Analysts: | 2.00 |
| Revenue Estimate Growth: | 0.15 |
| Eps Trend Current: | -0.50 |
| Eps Trend7days Ago: | -0.50 |
| Eps Trend30days Ago: | -0.50 |
| Eps Trend60days Ago: | -0.50 |
| Eps Trend90days Ago: | -1.10 |
| Date: | 2022-09-30 |
| Date: | 2022-06-30 |
| Date: | 2022-03-31 |
| Date: | 2021-12-31 |
| Revenue Estimate Avg: | 68020000.00 |
| Revenue Estimate Low: | 60100000.00 |
| Revenue Estimate High: | 80000000.00 |
| Revenue Estimate Number Of Analysts: | 4.00 |
| Revenue Estimate Growth: | 0.40 |
| Date: | 2019-12-31 |
| Period: | +1y |
| Revenue Estimate Avg: | 58300000.00 |
| Revenue Estimate Low: | 54500000.00 |
| Revenue Estimate High: | 61000000.00 |
| Revenue Estimate Number Of Analysts: | 5.00 |
| Revenue Estimate Growth: | 0.82 |
| Eps Trend7days Ago: | -0.68 |
| Eps Trend30days Ago: | -0.68 |
| Eps Trend60days Ago: | -0.68 |
| Eps Trend90days Ago: | -0.68 |
| Date: | 2019-06-30 |
| Period: | +1q |
| Revenue Estimate Avg: | 32040000.00 |
| Revenue Estimate Low: | 30200000.00 |
| Revenue Estimate High: | 35000000.00 |
| Revenue Estimate Number Of Analysts: | 5.00 |
| Revenue Estimate Growth: | 0.38 |
| Date: | 2019-03-31 |
| Revenue Estimate Avg: | 32040000.00 |
| Revenue Estimate Low: | 30200000.00 |
| Revenue Estimate High: | 35000000.00 |
| Revenue Estimate Number Of Analysts: | 5.00 |
| Revenue Estimate Growth: | 0.38 |
| Date: | 2018-12-31 |
| Revenue Estimate Avg: | 32040000.00 |
| Revenue Estimate Low: | 30200000.00 |
| Revenue Estimate High: | 35000000.00 |
| Revenue Estimate Number Of Analysts: | 5.00 |
| Revenue Estimate Growth: | 0.38 |
| Eps Trend7days Ago: | -0.92 |
| Eps Trend30days Ago: | -0.92 |
| Eps Trend60days Ago: | -0.92 |
| Eps Trend90days Ago: | -0.92 |
| Date: | 2022-12-31 |
| Eps Actual: | -1.2 |
| Date: | 2021-12-31 |
| Eps Actual: | -1.9 |
| Date: | 2020-12-31 |
| Eps Actual: | -1.1 |
| Date: | 2019-12-31 |
| Eps Actual: | -1.0 |
| Date: | 2018-12-31 |
| Eps Actual: | -1.8 |
| Date: | 2016-12-31 |
| Eps Actual: | -1.2 |
| Date: | 2015-12-31 |
| Eps Actual: | -0.6 |